hypercalcaemia of malignancy
Oncology · 2016–2018
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| zoledronic acid Treatment of multiple myeloma, bone metastases from breast cancer or castration-resistant prostate cancer, and hypercalcaemia of malignancy. | Jul 2018 | Recommended with restriction | no section in document |
| denosumab Treatment of hypercalcaemia of malignancy that is refractory to intravenous bisphosphonate therapy. | Mar 2016 | Deferred | none received |
What the PBS pays
$340M in government benefit over 2024–25, across 1,407,129 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| denosumab | $336.2M |
| zoledronic acid | $3.7M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| pamidronate disodiumPAMISOL pamidronate disodium 15mg/5mL injection vial | 2000 | 4 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.